Morning Brief — Tuesday, September 29, 2026

Market Overview

Today’s session is shaped by a bifurcated tape — biotech and small-cap momentum names are dominating the gainers list while broader macro catalysts remain sparse with no general market headlines to drive direction. CarMax’s +11% earnings reaction and Carnival’s +13% pop from yesterday signal that consumer-facing cyclicals are catching a bid, suggesting the market is pricing in a more resilient consumer than feared. The absence of macro news keeps the day stock-picker-driven, with sector rotation into beaten-down names the dominant theme.

Claude’s Call

UP — The earnings-driven momentum from CCL and KMX, combined with broadly bullish WSB sentiment in the mega-cap tech names (MU and NVDA both near 6-month highs), gives the tape a mild upward lean today. No macro headwinds in sight and end-of-quarter window dressing by institutional players should provide a modest bid into the close.

Top Movers

KOD (+177.96%) — $89.92 → $106.32 (+18.2% upside) Thesis: This is the headline mover of the day — nearly 3x in a single session with zero news attached. Without a confirmed catalyst, this screams either a short squeeze or a clinical/regulatory binary event that hasn’t hit the wires yet. KOD is a micro-cap name that has run from a 6-month low of $29.61 to $89.92, which is an extraordinary move. At the 6-month high, it’s already extended, and the SMA-50 at $40.30 is miles below — there is no technical floor nearby. This is almost certainly a trap for chasers. Vol ratio of 0.27 (below average) is a red flag — this move isn’t confirmed by volume conviction. Levels: Exit at Fib ext 1.272 at $106.32 if you’re already in. Support — don’t kid yourself — Fib 23.6% at $75.69 is the nearest meaningful level, a -16% drop from here.

KMX (+11.11%) — $62.83 → $71.82 (+14.3% upside) Thesis: This is the real deal. CarMax reported EPS of $1.61 — a clean earnings beat driving an 11% single-day pop, which is the strongest fundamentally-backed move on today’s list. Used car affordability remains a live theme as consumers trade down from new vehicles, and KMX is the dominant player in the fragmented used auto retail space. Technically, it’s punching through prior 20-day resistance at $63.29, sitting just below the 6-month high of $64.22. A clean breakout above $64.22 opens the door to the Fib 1.272 extension at $71.82. The SMA-50 at $59.48 provides solid downside support for a pullback entry. Levels: Exit at $71.82 (Fib 1.272 extension). Support at SMA-50 $59.48 / Fib 23.6% $57.62.

IOVA (+18.93%) — $13.07 → $15.49 (+18.5% upside) Thesis: Iovance Biotherapeutics is up nearly 19% and is sitting at a fresh 6-month high of $12.88, having rallied from a $3.30 low — a multi-bagger move in 6 months driven by its TIL (tumor-infiltrating lymphocyte) therapy platform, specifically lifileucel’s commercial momentum post-FDA approval. No fresh news today, but the stock is likely benefiting from biotech sector momentum and potential institutional accumulation ahead of upcoming data catalysts. At RSI 50 and trading at its 6-month high with a SMA-50 of $7.69 far below, the risk/reward depends entirely on whether you believe in the product cycle. Volume ratio of 0.38 is soft — conviction is lacking on this specific session’s move. Levels: Exit at Fib 1.272 $15.49. Support at Fib 23.6% $10.62.

BE (+7.73%) — $283.19 → $292.43 (near-term) / $407.41 (extended) Thesis: Bloom Energy is up 7.7% today, continuing a multi-week recovery from the $119 low. The energy transition / distributed power theme remains a strong secular tailwind — data center power demand and clean energy infrastructure spending are real and growing drivers for Bloom’s solid oxide fuel cell business. Technically, BE is approaching the Fib 23.6% retracement at $292.43 (which in this case acts as resistance from the prior high of $345.85), just below the 20-day high of $288.70. SMA-50 at $232.37 provides the key structural floor. This is a legitimate theme with a legitimate setup — not a sympathy trade. The 6-month range from $119 to $346 means there’s a massive recovery still in play if fundamentals hold. Levels: Exit near-term at $292 (Fib 23.6%). Full extension target $407 (Fib 1.272). Stop near SMA-50 $232.

PS (+5.36%) — $59.17 → $68.70 (+16.1% upside) Thesis: PagerDuty (PS) is up 5.4% today and +22.7% on the week — a significant multi-session move suggesting either an earnings pre-announcement, analyst upgrade, or institutional accumulation in the digital operations/AIOps space. Trading at the 6-month high of $59.17 after recovering from $24.12 — a 145% rally in 6 months. The SMA-50 at $40.63 is the long-term anchor. With no news, I’d treat this as a technical breakout that needs volume confirmation — the vol ratio of 0.03 is concerning and screams low-conviction breakout. Could be a thin-float momentum play. Risk of a reversal is elevated at these levels. Levels: Exit at $68.70 (Fib 1.272 extension). Support at Fib 23.6% $50.90 — that’s a painful 14% stop.

HHH (+8.07%) — $73.95 → $78.71 (+6.4% upside) Thesis: Howard Hughes Holdings is making a notable move toward its 6-month high of $74.76, trading at the top of its range with the SMA-50 at $65.48 providing strong support. Real estate/master planned community developers benefit from a “soft landing” narrative and declining rate expectations, which is likely driving this sector rotation move. No specific news catalyst, but technically this is a clean setup at range highs with well-defined support below. Levels: Exit at $78.71 (Fib 1.272). Support at SMA-50 $65.48 / Fib 23.6% $71.33.

Headlines to Watch

  • CarMax Q2 EPS $1.61 — Used auto market resilience on display — KMX’s clean beat signals the consumer is still trading into used vehicles; watch for read-through to CVNA and AutoNation.
  • Carnival +13% post-earnings — Cruise bookings remain well ahead of capacity — Confirms the “experiences over goods” consumer trend; travel and leisure names may continue to get a bid this week.
  • Bloom Energy (BE) sustaining 7%+ gains on no news — Watch whether the data center power demand narrative drives further institutional buying; BE is a leveraged play on AI infrastructure power constraints.
  • MU dominating WSB with 190 mentions ahead of potential earnings — Micron’s quarterly report is a key semiconductor sentiment read; a beat could catalyze a broader chip rally, miss could drag NVDA/AMD with it.
  • End-of-quarter window dressing (Q3 ends today, Sept 30) — Institutional managers will be adding winners and jettisoning losers into close; expect exaggerated moves in both directions in thin names.
  • Biotech broadly bid — IOVA, ADMA, LQDA, XNCR all up 7%+ — When multiple unrelated biotech names rally together without news, it’s often institutional rotation into the sector; check XBI for confirmation.
  • SMMT +15% with no catalyst — Summit Therapeutics is an oncology name that’s been volatile; without a data readout or deal announcement, this move is a potential short squeeze that could reverse hard.

Claude’s Top Picks

KMX (+11.11% today, +10.54% week) — $62.83 → $71.82 (+14.3% upside) Valuation: CarMax trades at a market-rate multiple for auto retail; the earnings beat justifies the re-rating and it’s not stretched vs. its own history post-pullback. Upside: Clean earnings catalyst with fundamental backing; used auto demand is sticky and the stock is breaking above 6-month resistance with room to the $71.82 Fib extension. Risk: If macro deteriorates or used auto pricing reverses, the 11% gap-up becomes a sell-the-rip setup; stop at SMA-50 $59.48.

BE (+7.73% today, +2.41% week) — $283.19 → $407.41 (+43.8% extended target) Valuation: Bloom Energy is a high-growth clean energy play where EV/Revenue is the relevant metric; the recovery from $119 suggests the market is repricing the AI power demand TAM expansion. Upside: Data center power infrastructure is a multi-year secular theme and Bloom’s fuel cell technology is directly in the path of demand; the $232 SMA-50 provides a strong floor for a swing trade. Risk: Bloom is pre-profitability territory — any rate spike or disappointment on customer contract announcements could send it back toward SMA-50 quickly; high volatility name.

ADMA (+7.89% today, +6.47% week) — $10.12 → $12.26 (+21.2% upside) Valuation: CHEAP — Forward P/E of 10.7x vs. peer median 15.9x, and EV/EBITDA of 10.4x vs. peer median 15.0x; this is the only genuinely cheap profitable name on the gainers list today. Upside: ADMA Biologics is a plasma-derived biologics company with 2% revenue growth and expanding margins; the valuation discount to peers is unwarranted for a profitable specialty pharma — this is a catch-up trade with a clear target at the Fib 1.272 extension of $12.26. Risk: Revenue growth of only 2% is slow for the sector; if the next quarter disappoints on top-line, the discount could persist rather than close. Stop at Fib 38.2% $9.86.

HHH (+8.07% today, +12.73% week) — $73.95 → $78.71 (+6.4% upside) Valuation: Real estate developers are rate-sensitive; with rate expectations declining, HHH’s master planned community model at these levels is reasonable — not expensive. Upside: Clean technical breakout toward 6-month high with SMA-50 at $65.48 providing a clear invalidation level; end-of-quarter window dressing favors adding winners. Risk: Any hawkish Fed re-pricing would pressure real estate names immediately; the 6.4% upside to the first extension target is modest relative to the position risk.

NTES (+4.88% today, +3.04% week) — $121.04 → $140.52 (+16.1% upside) Valuation: NetEase trades at a discount to U.S. gaming peers on most metrics; China tech re-rating and dollar weakness provide a macro tailwind on top of the company’s strong gaming pipeline. Upside: NTES is breaking above its 20-day high of $121.78 and the Fib 50% support at $121.06 is acting as a launchpad; the Fib 1.272 extension at $140.52 is a clean swing target. Risk: China regulatory risk is never fully off the table — any gaming license restriction news or geopolitical escalation could cut this move in half overnight. Stop at $118.09 (Fib 61.8%).

Avoid

KOD (+177.96%) — Trading at the 6-month high with below-average volume (vol ratio 0.27) and zero news catalyst; this has all the hallmarks of a short squeeze or pump that will give back 50%+ once momentum exhausts — there is no Fib support until $75.69, a 16% drop, and the real floor is the $40 SMA-50.

PS (+5.36%, +22.7% week) — Up 145% in 6 months and sitting at the 6-month high with a volume ratio of 0.03 — this is the lowest-conviction breakout on the list; without a real fundamental catalyst, chasing PagerDuty at these levels risks a sharp reversal back toward the $50.90 Fib support.

SMMT (+15.15%) — Summit Therapeutics is trading below its 6-month Fib retracement levels (23.6% support is at $23.09, well above the current price of $17.83), meaning the stock is still in a downtrend structure despite today’s pop; without a clinical data catalyst confirmed on the wires, this 15% move in an oncology name is extremely high-risk to hold overnight.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish) Claude says: AGREE — Micron is the highest-conviction name in the WSB crowd right now and for good reason; the stock at $1,062 is holding above the Fib 23.6% support of $1,002 after pulling back from the $1,213 high, and with AI-driven DRAM/HBM demand accelerating, the setup is technically healthy — but position sizing matters here because MU is a volatile binary on earnings.

NVDA — WSB says: BULLISH (80% bullish) Claude says: AGREE — NVDA at $231 is trading at its 6-month high of $235.20 with SMA-50 at $216.89 providing strong support; the AI infrastructure capex cycle is not over and NVDA’s monopoly on H100/B100 GPU demand makes this a fundamentally supported long — the chart agrees with the crowd here.

META — WSB says: MIXED (55% bullish) Claude says: PARTIALLY — META at $724 is pulling back from the $777 high and sitting right at Fib 23.6% support of $720.45, which is a technically interesting entry level; the mixed sentiment is appropriate — this is a show-me-the-AI-monetization story now and the stock needs to prove out Reality Labs or ad pricing acceleration to justify the next leg higher.

AMD — WSB says: MIXED (55% bullish) Claude says: PARTIALLY — AMD at $609 has had a monster run from $196 and is approaching the 6-month high of $630.63 with SMA-50 at $509; the mixed sentiment is right because AMD is playing second fiddle to NVDA in AI chips — the data center GPU story is real but AMD needs a catalyst (major model adoption of MI300X) to break out of NVDA’s shadow and close the valuation gap.

RDDT — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Reddit is pulling back hard from its $203 high and is currently trading at $144.93, below the Fib 61.8% support of $154.36 and under the SMA-50 of $158.02 — the chart is in distribution mode, not accumulation; WSB being bullish on their own platform’s stock while it’s making lower highs is textbook community bias, not analysis.

Earnings Scorecard

CCL — REPORTED | EPS: $2.22 | Stock: +13.2% | Reaction: Justified and then some. Carnival’s $2.22 EPS in a post-COVID cruise cycle represents remarkable demand durability — the 13% single-day pop reflects genuine surprise at the magnitude of profitability, and the booking-forward commentary is clearly constructive; this is not a sell-the-rip, it’s a hold with room to the prior highs.

KMX — REPORTED | EPS: $1.61 | Stock: +11.1% | Reaction: Justified — buy the dip on any pullback. An 11% gap-up on an earnings beat in a beaten-down used auto retailer is textbook re-rating; the Fib 1.272 extension at $71.82 is the near-term target, and any pullback to the SMA-50 at $59.48 is a gift.

JBL — REPORTED | EPS: $8.01 | Stock: +1.3% | Reaction: Muted — likely priced in. Jabil’s solid EPS print got a yawn from the market; the 1.3% reaction suggests consensus was already expecting strong numbers — no edge in chasing this one.

FDS — REPORTED | EPS: $15.18 | Stock: -0.9% | Reaction: Mild miss in guidance likely offset a solid print. FactSet’s flat-to-negative reaction on a $15.18 EPS print suggests the market was focused on forward guidance or organic growth trajectory rather than the headline number — neutral, not a dip-buy catalyst.

CAG — REPORTED | EPS: -$3.95 | Stock: -0.9% | Reaction: Surprisingly muted given the massive EPS loss. ConAgra printing a -$3.95 EPS (likely including impairments/write-downs) and only dropping 0.9% means either the loss was well-telegraphed or the underlying operational cash flow told a better story — avoid until management clarifies the charge-off details.

MKC — REPORTED | EPS: $6.01 | Stock: -0.5% | Reaction: Sell-the-news on a crowded defensive name. McCormick’s slight decline despite a decent EPS print is classic defensive fatigue — investors rotated out of the safety trade as risk appetite returned post-CCL/KMX; hold if you own it, don’t chase.

JEF — REPORTED | EPS: $3.58 | Stock: -0.4% | Reaction: Investment banking beat expectations but trading revenue concerns may be weighing. Jefferies’ flat-to-down reaction suggests the market wants to see dealmaking acceleration sustain before re-rating the stock — neutral hold, not actionable today.

All price targets based on Fibonacci extension analysis from 6-month swing data. This brief is for informational purposes only and does not constitute financial advice. Past performance does not guarantee future results.